Thank You Seel:
Here are a few posts from YMB from aj, who's been in the stock since IPO and adding every month:
ajabraham2002 • Jul 25, 2013 7:58 PM
If You Really Thought the Market Cap. Was 1-3 Million...
you really shouldn't be making unequivocal predictions about the share price. The warrants have always been a huge part of the equation. The article that came out two days ago argued that this is a value trap b/c Yahoo! finance shows a market cap of less than 5 million. Give me a break. People who buy on that basis are the most marginal shareholders imaginable. I have gone to a shareholder meeting. I have seen the urinary conduit up close, in a sealed container. I have spoken to the CFO in person. This is a legitimate company run by smart people trying to develop technology invented by brilliant, world-class medical doctors and scientists. You buy this company if you believe in the regenerative potential of autologous stem cells and if you believe that Dr. Atala, with his decades-long head start, is the scientist most likely to deliver first and deliver best on that potential.
ajabraham2002 • Jul 2, 2013 1:01 PM
I think a lot of small shareholders bought at the IPO and have since been busted out of this name, big time. The vast majority of the company is owned by Celgene and a few other private equity and venture capital firms in the form of convertible debt and warrants that appear the value the company at b/w .69 and .75 per share, currently. The warrants that were issued during the previous round of financing expire in early 2014. I'm not sure about the duration of the ones issued during the current round. With Celgene, a 50 billion dollar market cap biotech, backing Tengion now wholeheartedly, I think the future is bright. They have the right of first refusal on all three pipeline products-- the neo-urinary conduit, neo-kidney augment and an esophageal product which is currently in the pre-clinical phase. The neo-kidney product, which should receive approval for human testing by the end of this year, is the first potential, blockbuster product as the dialysis/kidney market is roughly 4 billion per year. If Tengion could receive just a fraction of that, it could potentially be an enormous catalyst. The neo-urinary conduit should complete phase I by the end of this year, and all indications are that it will be deemed a safe substitute for the current method. I believe eventually regenerative medicine will revolutionize medical care, and Tengion is CLEARLY at the forefront of the industry. Yesterday's news is probably the most significant news to ever come out pertaining to this company, and the price action confirms it. On a technical basis, resistance in the .69-.75 range should be fairly intense, but when it is broken, I think this stock could really take off. Lastly, as I stated, I believe the board is empty b/c so many small shareholders have been eliminated during the swoon from $50 to .30. Those who are left are partnered with some of very knowledgeable and deep-pocketed investors. These are all just my opinions, though, and not professional advice
GLTA
